World Health Organization Issues Concern Over Acute Shortage of Obesity Jabs
Fewer than 10% of patients eligible to benefit from weight-loss injections including Wegovy have access to them, states the World Health Organization as it releases its initial recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is urging broader and more equitable access to this class of drugs.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our new guidelines recognises that excess weight is a chronic disease that can be addressed with comprehensive and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major barriers to widespread access to the injections that can aid individuals in losing substantial body mass, notes the organization.
Skinny Jab Supply Crisis
Even in the current best projected scenario, the supply of such drugs might only reach around 100 million people – less than 10% of the global need, per the health organization.
The advice encourages nations and manufacturers to expand access, by measures like patent sharing.
Exclusive production rights on semaglutide – the core ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Drugs Operate
These medications replicate a natural hormone to slow digestion, reduce hunger and increase the sense of being full so individuals reduce food intake.
People commonly see weight reduction within a few weeks of beginning the once-weekly jabs.
Evidence indicates users may regain a significant portion within a year of discontinuing the treatment, as their normal appetite come back.
To be carrying excess weight increases your risk for contracting diseases, such as type 2 diabetes, heart disease, stroke, and certain cancers.
Excess weight concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
